Summary: The donut hole was the coverage gap where Part D beneficiaries once paid a higher share of drug costs mid-year. The Inflation Reduction Act eliminated it starting in 2025, replacing it with a simple structure: deductible, 25 percent coinsurance, and a $2,100 out-of-pocket cap. This guide explains what the gap was, why it existed, what replaced it, and what old advice you should now ignore.
For two decades, explaining Part D meant explaining the donut hole: the bizarre stretch of the benefit where coverage got worse before it got better. Beneficiaries planned their drug spending around it, timed refills to avoid it, and dreaded falling into it. As of 2025, it is gone, and a lot of the advice written about it is now actively misleading.
This guide is the cleanup crew: what the gap was, what killed it, and which old rules of thumb to retire.
The donut hole survived from 2006 to 2024 because closing it cost money and the politics never aligned until the IRA. The Affordable Care Act began phasing the gap down in 2011, cutting beneficiary cost-sharing in the gap gradually, but full elimination kept slipping. Each reform made the gap less painful without removing the complexity: beneficiaries still had to track which phase they were in.
The IRA finally removed the phase rather than softening it, funded partly by shifting catastrophic-phase costs to plans and manufacturers. That funding shift is also why premiums needed temporary stabilization: the money for the cap comes from somewhere, and the somewhere is the supply side of the market.
From 2006 through 2024, Part D had four phases: deductible, initial coverage, the coverage gap, and catastrophic coverage. In the gap, beneficiaries paid a higher share of drug costs, historically 100 percent, later reduced by law to 25 percent for brands and generics. You entered the gap after your total drug costs crossed a threshold, and exited into catastrophic coverage after your out-of-pocket crossed another.
The gap was a cost-control device from the original 2003 legislation: a way to limit the program's liability by making beneficiaries pay more in the middle. It created perverse incentives, like beneficiaries splitting pills or skipping doses in the gap months, and it punished exactly the sickest beneficiaries the program was meant to protect.
The IRA restructured the benefit starting in 2025: the coverage gap was eliminated and replaced with a single initial-coverage phase at 25 percent coinsurance running straight into a $2,000 out-of-pocket cap ($2,100 in 2026). The law also shifted more of the catastrophic-phase liability onto plans and manufacturers, which is why premiums needed the stabilization demonstration to stay orderly.
The result is the simplest Part D benefit in the program's history: deductible, 25 percent, cap. Three numbers replace the four-phase maze, and the cap is lower than what many beneficiaries used to spend inside the gap alone.
2026 in full: you pay the first $615 (deductible), then 25 percent of covered drug costs, until your out-of-pocket total reaches $2,100, after which covered drugs cost $0. There is no phase where your share jumps. A beneficiary with $10,000 in drug costs pays $615 plus 25 percent of $9,385, which is $2,961, capped at $2,100. Under the old benefit that same beneficiary could have paid far more.
Manufacturer discounts still exist in the background: drug makers now pay into the program in the catastrophic phase, which funds part of the cap. You do not need to understand the plumbing; you need to know your share is capped and the gap is gone.
Retire the refill-timing strategies. Articles advising you to stock up before 'falling into the donut hole' describe a world that ended in 2024. Retire the fear of mid-year cost spikes: your coinsurance rate is now flat from deductible to cap. Retire the catastrophic-phase math: there is no more 5 percent coinsurance stretching to infinity; the cap is a hard stop.
Keep one piece of old advice: the formulary still rules everything. The gap's elimination did not change which drugs your plan covers, and non-covered drugs still sit outside all the protections.
The biggest winners are beneficiaries with high drug costs who used to spend heavily in the gap: cancer patients, people on biologics, and anyone with specialty-tier prescriptions. For a beneficiary with $30,000 in annual drug costs, the old benefit could mean $7,000 or more out of pocket; the new benefit caps it at $2,100 plus premiums.
Light users barely notice the change, which is fine: they were never the ones the gap hurt. The reform was targeted at the tail, and the tail is where it lands.
The cap is indexed to Part D spending growth, so expect it to rise most years: $2,400 is already set for 2027. Plan premiums are the wild card as the stabilization demonstration ends; CMS projects the average standalone premium ticking up modestly, but individual plans will vary more.
The structural lesson: Part D is now a capped benefit, which makes it plannable. The remaining uncertainty is premiums and formularies, both of which you re-shop every open enrollment. The gap era's complexity is not coming back.
No. The coverage gap was eliminated starting in 2025 under the Inflation Reduction Act. You now pay 25% after the deductible until the $2,100 out-of-pocket cap.
A coverage gap in the old Part D benefit where beneficiaries paid a higher share of drug costs after initial coverage ran out and before catastrophic coverage began.
Historically up to 100% of drug costs in the gap; later law reduced it to 25%. High drug-cost beneficiaries could still pay thousands a year.
In effect, yes: after the $2,100 cap, covered drugs cost $0. But there is no separate phase with its own cost-sharing to calculate.
Benefit structure per the Inflation Reduction Act and CMS 2026 parameters. This guide is for planning only.